Daily Caller
RFK’s Calls To Ban One Of Big Pharma’s Most Powerful Tools Rattle Drugmakers Despite Uncertain Political Prospects

From the Daily Caller News Foundation
By Adam Pack
“The primary purpose of pharmaceutical advertising is not to influence consumers, but rather the television networks and news itself”
President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to helm the Department of Health and Human Services(HHS) is reportedly rattling drugmakers in light of Kennedy’s prior calls to ban pharmaceutical advertising.
If confirmed by the Senate to serve as HHS secretary, Kennedy could marshal the country’s public health agencies to implement his Make America Healthy Again (MAHA) priorities, leading one pharmaceutical industry observer to claim that Kennedy is likely to attempt a ban on direct-to-consumer (DTC) drug advertising. However, any attempt from Kennedy to crack down on pharmaceutical advertising would almost certainly be challenged by drugmakers on First Amendment grounds and may lack the support of Trump and Republican lawmakers who have so far refrained from commenting on Kennedy’s proposal.
“One of the things I’m going to advise Donald Trump to do in order to correct the chronic disease epidemic is to ban pharmaceutical advertising on TV,” Kennedy said to thunderous applause during a Tucker Carlson Live Tour event in Glendale, Arizona, on Oct. 31. “There’s only two countries in the world that allow pharmaceutical advertising on the airwaves. One of them is New Zealand and the other is us and we have the highest disease rate, and we buy more drugs and they’re more expensive than anywhere in the world.”
Spending on DTC pharmaceutical advertising in the United States ballooned to more than $7 billion in 2023, with ad buys on weight loss and diabetes drugs surpassing $1 billion for the first time, according to analysis from MediaRadar.
‘Threat To The Public Good’
“Whilst we have a relatively benign view of RFK’s impact on the Pharma industry, one thing that does worry us is the potential for the U.S. government to ban DTC advertising of drugs,” United Kingdom-based research firm Intron Health wrote in a report excerpted by FiercePharma, a pharmaceutical industry-focused news outlet. “We see this as the biggest imminent threat from RFK and the new Trump administration.”
Kennedy could wield considerable influence over the second Trump administration’s approach to pharmaceutical advertising since the Food and Drug Administration (FDA) — the chief regulator of the pharmaceutical industry’s advertisements — is housed within HHS.
The Biden FDA issued new guidelines on DTC advertising that went into effect on May 20, requiring advertising to state drugs’ side effects and medication risks in a “clear, conspicuous, and neutral manner.” Kennedy called for a review of these guidelines in an op-ed in The Wall Street Journal published on Sept. 5.
During his run for president and as a Trump campaign surrogate, Kennedy claimed that media outlets who receive substantial ad revenue from pharmaceutical companies cannot report on Big Pharma with objectivity.
“The primary purpose of pharmaceutical advertising is not to influence consumers, but rather the television networks and news itself,” according to a statement on Kennedy’s website. “It gives Big Pharma the power to dictate what goes on the news — and what doesn’t — because the networks won’t bite the hand that feeds them.”
“Every other country in the world recognizes that pharma ads represent a threat to the public good,” Kennedy’s website also claims.
Kennedy’s concern that mainstream media has been co-opted by the pharmaceutical industry to buy news outlets’ silence on scrutinizing drugmakers in exchange for ad revenue has been embraced by influential voices in the MAHA movement and other Trump allies.
“The news ad spending from pharma is a public relations lobbying tactic, essentially to buy off the news,” Calley Means, a Kennedy advisor and MAHA advocate, told Tucker Carlson during an interview on Feb 2. “The news is not investigating pharma.”
“No advertising for pharma,” Elon Musk wrote on X on Nov. 19 in response to a post alleging a correlation between the growth of pharmaceutical advertising and rising media bias.
Dr. Jay Bhattacharya, Trump’s nominee to lead the National Institutes of Health, has also argued that media organizations that rake in pharmaceutical advertising revenue should face increased scrutiny when reporting on public health matters. Bhattacharya was notably blacklisted by Twitter before Musk bought the platform over his criticism of the medical establishment’s lockdown approach to the COVID-19 pandemic.
“Another argument against direct-to-consumer advertising by drug companies: Because of DTC ads, drug companies like Pfizer hold a vice grip on the editorial policies of conventional American media, which can ill afford to lose the advertising money,” Bhattacharya wrote on X on May 30, 2023.
Dr. Marty Mackary, Trump’s pick to lead the FDA, has not commented on Kennedy’s proposal nor allegations that the mainstream media has been corrupted by the pharmaceutical industry.
Ban Denies ‘Opportunity To Be Informed’
Although a ban on pharmaceutical advertising would put the U.S. more in line with the rest of the world, an attempted prohibition of the practice by the incoming Trump administration would likely infringe upon the First Amendment’s protection of “commercial speech,” according to Dr. Jeffrey Singer, a general surgeon and senior fellow at the libertarian-leaning Cato Institute.
“His calls to ban pharmaceutical advertising violate the First Amendment right to freely share and exchange information, including scientific information, and infringe on the individual right to self-medicate,” Singer wrote in a statement following Trump’s nomination of Kennedy to serve as HHS secretary.
Banning pharmaceutical advertising would also make Americans less informed about the availability of drugs and their side effects and widen the information gap between medical practitioners and patients, an apparent contradiction to Kennedy’s pledge to fight for Americans’ ability to question the medical establishment and do their own research, Singer told the Daily Caller News Foundation in an interview.
“On the one hand, RFK Jr. says — and I agree with him — that people need to be empowered. They need to do their own due diligence. We should be doing our own investigations,” Singer told the DCNF. “Well, how are you going to do that if you are barred from hearing what the pharmaceutical companies have to say about their medication, and its risks and benefits and side effects, which the FDA requires them to mention?”
“If you want an empowered population of adults to be able to do their own due diligence, you can’t block them from the information that a pharmaceutical [ad] is going to give them — especially when they’re [pharmaceutical companies] allowed to give it to healthcare practitioners,” Singer added. “Denying us the information actually denies us the opportunity to be informed.”
Uncertain Political Prospects
Kennedy’s call to ban pharmaceutical advertising is likely to face skepticism from Republican lawmakers who have traditionally preferred a deregulatory approach to the pharmaceutical industry. The current legislative effort to ban DTC pharmaceutical advertising in Congress has no support from Republican lawmakers.
“Sometimes when I hear his [Kennedy’s] agenda discussed, people are like ‘sounds great — he’s never going to do it’. There’s zero chance he’s going to be able to undo these conflicts of interests and the power of Big Ag and these Republican lawmakers who have a lot of big donors in these industries,” Megyn Kelly told Casey Means, during a Nov. 20 interview on her show about whether Kennedy’s MAHA priorities have enough support to be achieved during the next four years.
The pharmaceutical industry notably has roughly 1800 registered lobbyists in the United States, and industry PACs have doled out more than $15 million to candidates this year.
Trump tried to further regulate pharmaceutical advertising during his first administration by requiring DTC ads on television to include the list price for nearly all drugs covered by Medicare and Medicaid. Three large drugmakers filed suit in response and a federal judge struck down the regulation before it went into effect, ruling that HHS overstepped its authority to compel drugmakers to include their list prices in advertising.
Trump’s transition team did not respond to the DCNF’s inquiry about whether the president-elect supports Kennedy’s advocacy to crack down on pharmaceutical advertising.
The Pharmaceutical Research and Manufacturers of America, a trade association that lobbies on behalf of the pharmaceutical industry, declined to comment on Kennedy’s calls to ban pharmaceutical advertising.
A Kennedy spokesperson did not respond to the DCNF’s request for comment.
Business
Will Trump’s ‘Liberation Day’ Tariffs End In Disaster Or Prosperity?

From the Daily Caller News Foundation
By J.D. Foster
“Liberation Day” has come. So what does it mean? Beats the hell out of me.
What we know is that President Trump’s avalanche of tariffs was to hit a peak on April 2; not end, mind you; not necessarily “the” peak, as more could be on the way; but a peak.
No Trump policy more completely breaks with America’s past than his “beautiful” tariffs on just about everything coming into the United States from just about anywhere.
Will this new policy liberate American manufacturing from foreign shackles? Will it usher in a new era of prosperity, keeping in mind the United States had for many years the consistently best-performing economy in the industrialized world, even overcoming the many inane obstacles erected by the Biden-Harris Administration?
Or will it leave the United States isolated, friendless, and weakened?
The correct answer at this point is no one knows, not even the bloviating talking heads on TV confidently predicting demise or Shangri-la.
Think of it this way. Suppose you’re a restaurant chef and a woman hands you a new recipe. Her father turns 75 soon and they want to have a party at the restaurant. The recipe is for the father’s favorite dish, one her mother made for years.
The recipe looks old, with odd ingredients and processes you’ve not seen before. Now judge it as a chef.
You can’t. Even as you start chopping and dicing, mixing ingredients as instructed, you’re not too sure how this is going to turn out. You have to wait until the dish is on the plate and taste it.
That’s the case with Trump’s tariffs. How will this all turn out? It’s too soon to tell.
The stock market sure doesn’t like it, but why should it? The investor class doesn’t understand this any better than you do. What they do understand is this new policy has upended assumptions and created enormous new uncertainties. We know that dish as those ingredients are always good for a big pullback.
Much of the confusion arises because we don’t know the underlying policy and likely this uncertainty is intentional. Trump likes keeping his counterparts, in this case our trading partners, guessing. If it means Americans are confused for a bit, Trump’s cool with that. Breaking eggs to make an omelette. It will pass and America will be great again afterward. Bon appetite.
If the core policy is to erect massive and mostly permanent tariff walls behind which American firms can hide, then we know how this will turn out: America, meet the dustbin of history.
If the core policy is to force our trading partners to deal with America fairly by reducing their trade barriers after which Trump will remove his tariffs, then this could turn out very well. Tariffs (and non-tariff barriers) in the U.S. and those of our trading partners would fall, reinvigorating the free trade that has energized prosperity for decades.
Which is it? Walls and doom or freedom and prosperity? Again, too early to tell.
Whatever else Trump does in his second term, these tariffs will define his presidency, akin in consequence to Ronald Reagan’s pro-growth tax cuts and Joe Biden’s inflation.
Trump in his second term clearly lives by the saying, “go bold or go home.” He’s got “bold” down pat. We will see over the next year or so whether he and the Republicans go home. Has he liberated Democrats from any fear of Republicans in the mid-terms or in 2028, or he’s liberated America from any fear of Democratic socialism and wokism returning in our lifetimes. The chips are all-in. Soon we will see the cards. Uncertainty, indeed.
JD Foster is the former chief economist at the Office of Management and Budget and former chief economist and senior vice president at the U.S. Chamber of Commerce. He now resides in relative freedom in the hills of Idaho.
Business
‘Time To Make The Patient Better’: JD Vance Says ‘Big Transition’ Coming To American Economic Policy

JD Vance on “Rob Schmitt Tonight” discussing tariff results
From the Daily Caller News Foundation
By Hailey Gomez
Vice President JD Vance said Thursday on Newsmax that he believes Americans will “reap the benefits” of the economy as the Trump administration makes a “big transition” on tariffs.
The Dow Jones Industrial Average dropped 1,679.39 points on Thursday, just a day after President Donald Trump announced reciprocal tariffs against nations charging imports from the U.S. On “Rob Schmitt Tonight,” Schmitt asked Vance about the stock market hit, asking how the White House felt about the “Liberation Day” move.
“We’re feeling good. Look, I frankly thought in some ways it could be worse in the markets, because this is a big transition. You saw what the President said earlier today. It’s like a patient who was very sick,” Vance said. “We did the operation, and now it’s time to make the patient better. That’s exactly what we’re doing. We have to remember that for 40 years, we’ve been doing this for 40 years.”
“American economic policy has rewarded people who ship jobs overseas. It’s taxed our workers. It’s made our supply chains more brittle, and it’s made our country less prosperous, less free and less secure,” Vance added.
Vance recalled that one of his children had been sick and needed antibiotics that were not made in the United States. The Vice President called it a “ridiculous thing” that some medicines invented in the country are no longer manufactured domestically.
“That’s fundamentally what this is about. The national security of manufacturing and making the things that we need, from steel to pharmaceuticals, antibiotics, and so forth, but also the good jobs that come along when you have economic policies that reward investing in America, rather than investing in foreign countries,” Vance said.
WATCH:
With a baseline 10% tariff placed on an estimated 60 countries, higher tariffs were applied to nations like China and Israel. For example, China, which has a 67% tariff on U.S. goods, will now face a 34% tariff from the U.S., while Israel, which has a 33% tariff, will face a 17% U.S. tariff.
“One bad day in the stock market, compared to what President Trump said earlier today, and I think he’s right about this. We’re going to have a booming stock market for a long time because we’re reinvesting in the United States of America. More importantly than that, of course, the people in Wall Street have done well,” Vance said.
“We want them to do well. But we care the most about American workers and about American small businesses, and they’re the ones who are really going to benefit from these policies,” Vance said.
The number of factories in the U.S., Vance said, has declined, adding that “millions of workers” have lost their jobs.
“My town [Middletown, Ohio], where you had 10,000 great American steel workers, and my town was one of the lucky ones, now probably has 1,500 steel workers in that factory because you had economic policies that rewarded shipping our jobs to China instead of investing in American workers,” Vance said. “President Trump ran on changing it. He promised he would change it, and now he has. I think Americans are going to reap the benefits.”
-
2025 Federal Election15 hours ago
Canada Continues to Miss LNG Opportunities: Why the World Needs Our LNG – and We’re Not Ready
-
COVID-191 day ago
Trump’s new NIH head fires top Fauci allies and COVID shot promoters, including Fauci’s wife
-
Freedom Convoy2 days ago
Freedom Convoy leaders Tamara Lich, Chris Barber found guilty of mischief
-
Business2 days ago
B.C. Credit Downgrade Signals Deepening Fiscal Trouble
-
2025 Federal Election1 day ago
Will Four More Years Of Liberals Prove The West’s Tipping Point?
-
2025 Federal Election1 day ago
Poilievre promises to drop ‘radical political ideologies’ in universities
-
Business1 day ago
‘Time To Make The Patient Better’: JD Vance Says ‘Big Transition’ Coming To American Economic Policy
-
2025 Federal Election13 hours ago
Mainstream Media Election Coverage: If the Election Was a NHL Game, the Ice Would be Constantly Tilted Up and to the Left